Last week Thursday, an FDA advisory panel recommended the approval of Novo Nordisk’s injectable drug liraglutide for the treatment of obesity.
A new study by Aetna’s Innovation Labs and GNS Healthcare uses “big data” analytics to predict patients at risk for metabolic syndrome. Their results show that lowering waist size and blood glucose have the largest health benefits and cause the biggest reduction in medical costs. Regular doctor visits and medication adherence reduces the one-year probability of having metabolic syndrome in nearly 90% of people.
Sign up to receive email updates!